Current and novel bronchodilators in respiratory disease

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 1, 2014, Pages 73-86

  Spina, Domenico ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

asthma; bronchodilation; COPD; long acting 2 agonist; long acting muscarinic antagonist

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIMAKALIM; BRONCHODILATING AGENT; CARMOTEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; IMIQUIMOD; INDACATEROL; ISOPRENALINE; L 9026885; LEMAKALIM; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PL 3994; PROPRANOLOL; RO 25 1553; RPL 554; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

ASTHMA; BRONCHODILATATION; CELL SURFACE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DRUG CHOICE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; MONOTHERAPY; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84890125835     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000012     Document Type: Review

References (92)

1. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64:450-504
2. Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem 2011; 242:31-50
3. Edelson JD, Makhlina M, Silvester KR, et al. In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His- Phe-D-Ala-Gly-Arg-D-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor: An agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther 2013; 26:229-238
4. Linden A, Hansson L, Andersson A, et al. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 2003; 58: 217-221
5. Benyahia C, Gomez I, Kanyinda L, et al. PGE(2) receptor (EP(4)) agonists: Potent dilators of human bronchi and future asthma therapy? Pulm Pharmacol Ther 2012; 25:115-118
6. Yoshii A, Iizuka K, Dobashi K, et al. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am J Respir Cell Mol Biol 1999; 20:1190-1200
7. Corompt E, Bessard G, Lantuejoul S, et al. Inhibitory effects of large Ca2+activated K+ channel blockers on beta-Adrenergic-And NO-Donor-mediated relaxations of human and guinea-pig airway smooth muscles. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:77-86
8. Muller-Schweinitzer E, Fozard Jr. SCA 40: Studies of the relaxant effects on cryopreserved human airway and vascular smooth muscle. Br J Pharmacol 1997; 120:1241-1248
9. Janssen LJ. Ionic mechanisms and Ca(2+) regulation in airway smooth muscle contraction: Do the data contradict dogmä Am J Physiol Lung Cell Mol Physiol 2002; 282:L1161-L1178
10. Faurschou P, Mikkelsen KL, Steffensen I, et al. The lack of bronchodilator effect and the short-Term safety of cumulative single doses of an inhaled potassium channel opener (bimakalim) in adult patients with mild to moderate bronchial asthma. Pulm Pharmacol 1994; 7:293-297
11. Kidney JC, Fuller RW, Worsdell YM, et al. Effect of an oral potassium channel activator, BRL 38227, on airway function and responsiveness in asthmatic patients: Comparison with oral salbutamol. Thorax 1993; 48:130-133
12. Calzetta L, Spina D, Page C, et al. The effect of the mixed phosphodiesterase 3/4 inhibitor Rpl554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 2013; 346:414-423
13. Franciosi LG, Zuiker R, Kamerling IM, et al. RPL554 a dual PDE3/4 inhibitor is well tolerated and maintains bronchodilator activity when administered by inhalation to mild to moderate allergic asthmatics on 6 consecutive days. Am J Respir Crit Care Med 2013; 187:A3875
14. Cazzola M, Calzetta L, Segreti A, et al. Safety and bronchodilator effects of nebulized RPL554 a novel dueal PDE3/4 inhibitor in COPD. Am J Respir Crit Care Med 2013; 187:A1497
15. Liggett SB. Bitter taste receptors on airway smooth muscle as targets for novel bronchodilators. Expert Opin Ther Targets 2013; 17:721-731
16. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol 2010; 159:265-284
17. Dekkers BGJ, RackéK, Schmidt M. Distinct PKA and Epac compartmentalization in airway function and plasticity. Pharmacol Ther 2013; 137:248-265
18. Drake MG, Scott GD, Proskocil BJ, et al. Toll-like receptor 7 rapidly relaxes human airways. Am J Respir Crit Care Med 2013; 188:664-672
19. Baur FO, Beattie D, Beer D, et al. The identification of indacaterol as an ultralong-Acting inhaled b2-Adrenoceptor agonist. J Med Chem 2010; 53: 3675-3684
20. Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-Acting b2-Adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 2012; 344:218-230
21. Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled b2-Adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett 2010; 20:1410-1414
22. Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new longacting beta 2-Adrenoceptor agonist, TA 2005. Eur J Pharmacol 1992; 227:403-409
23. Aparici M, Gomez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled b2-Adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther 2012; 342:497-509
24. Jacobsen JR, Choi SK, Combs J, et al. A multivalent approach to the discovery of long-Acting b2-Adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett 2012; 22:1213-1218
25. Lin Y, Smrcka AV. Understanding molecular recognition by G protein bg subunits on the path to pharmacological targeting. Mol Pharmacol 2011; 80:551-557
26. Roscioni SS, Maarsingh H, Elzinga CRS, et al. Epac as a novel effector of airway smooth muscle relaxation. J Cell Mol Med 2011; 15:1551-1563
27. Zieba BJ, Artamonov MV, Jin L, et al. The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of rhoA activity. J Biol Chem 2011; 286:16681-16692
28. Janssen LJ, Tazzeo T, Zuo J. Enhanced myosin phosphatase and Ca(2+)-uptake mediate adrenergic relaxation of airway smooth muscle. Am J Respir Cell Mol Biol 2004; 30:548-554
29. Reiter E, Ahn S, Shukla AK, et al. Molecular mechanism of b-Arrestin-biased agonism at seven-Transmembrane receptors. Ann Rev Pharmacol Toxicol 2012; 52:179-197
30. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: Biasing seven-Transmembrane receptors. Nat Rev Drug Discov 2010; 9: 373-386
31. Walker JKL, Penn RB, Hanania NA, et al. New perspectives regarding b2-Adrenoceptor ligands in the treatment of asthma. Br J Pharmacol 2011; 163: 18-28
32. Dickey BF, Walker JKL, Hanania NA, et al. b-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol 2010; 10:254-259
33. Kahsai AW, Xiao K, Rajagopal S, et al. Multiple ligand-specific conformations of the b2-Adrenergic receptor. Nat Chem Biol 2011; 7:692-700
34. Rajagopal S, Ahn S, Rominger DH, et al. Quantifying ligand bias at seventransmembrane receptors. Mol Pharmacol 2011; 80:367-377
35. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 1983; 220:141-162
36. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of betablocker action: Carvedilol stimulates beta-Arrestin signaling. Proc Natl Acad Sci U S A 2007; 104:16657-16662
37. Liu JJ, Horst R, Katritch V, et al. Biased signaling pathways in beta2-Adrenergic receptor characterized by 19F-NMR. Science 2012; 335: 1106-1110
38. Sykes DA, Charlton SJ. Slow receptor dissociation is not a key factor in the duration of action of inhaled long-Acting b2-Adrenoceptor agonists. Br J Pharmacol 2012; 165:2672-2683
39. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-h-long duration of action of olodaterol. J Pharmacol Exp Ther 2011; 337:600-609
40. Battram C. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2- one (Indacaterol), a novel inhaled beta2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317:762-770
41. Rosethorne EM, Turner RJ, Fairhurst RA, et al. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-Adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 2010; 382:255-263
42. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38:533-547
43. Patel S, Summerhill S, Stanley M, et al. The reassertion profiles of long acting beta2-Adrenoceptor agonists in the guinea pig isolated trachea and human recombinant beta2-Adrenoceptor. Pulm Pharmacol Ther 2011; 24:247-255
44. Coleman RA. On the mechanism of the persistent action of salmeterol: What is the current position? Br J Pharmacol 2009; 158:180-182
45. Anderson GP, Linden A, Rabe KF. Why are long-Acting beta-Adrenoceptor agonists long-Acting? Eur Respir J 1994; 7:569-578
46. Szczuka A, Wennerberg M, Packeu A, et al. Molecular mechanisms for the persistent bronchodilatory effect of the b2-Adrenoceptor agonist salmeterol. Br J Pharmacol 2009; 158:183-194
47. Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 2010; 161: 488-508
48. Ortega VE, Wechsler ME. Asthma pharmacogenetics. Curr Opin Allergy Clin Immunol 2013; 4:399-409
49. Thomsen M, Nordestgaard BG, Sethi AA, et al. b2-Adrenergic receptor polymorphisms, asthma and COPD: Two large population-based studies. Eur Respir J 2011; 39:558-566
50. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to long acting beta2-Agonist therapy: A pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-2125
51. Bleecker ER, Nelson HS, Kraft M, et al. b2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181:676-687
52. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-Adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): A genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374:1754-1764
53. Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011; 128:315-322
54. Page CP, Spina D. Beta2-Agonists and bronchial hyperresponsiveness. Clin Rev Allergy Immunol 2006; 31:143-162
55. Cockcroft DW, Sears MR. Are inhaled longacting b2 agonists detrimental to asthmä Lancet Respir Med 2013; 1:339-346
56. Cheung D, Timmers MC, Zwinderman AH, et al. Long-Term effects of a longacting beta2-Adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198-1203
57. Lipworth B, Tan S, Devlin M, et al. Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 1998; 104:431-438
58. Haney S, Hancox RJ. Rapid onset of tolerance to beta-Agonist bronchodilation. Respir Med 2005; 99:566-571
59. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with longacting beta-Agonists, a randomised controlled trial. Respir Res 2005; 6:107
60. Wraight JM, Hancox RJ, Herbison GP, et al. Bronchodilator tolerance: The impact of increasing bronchoconstriction. Eur Respir J 2003; 21:810-815
61. Giembycz MA. An estimation of beta 2-Adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. Br J Pharmacol 2009; 158:287-299
62. Oakley RH, Laporte SA, Holt JA, et al. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000; 275:17201-17210
63. Lee DK, Currie GP, Hall IP, et al. The arginine-16 beta2-Adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004; 57:68-75
64. Walker JKL, Fong AM, Lawson BL, et al. b-Arrestin-2 regulates the development of allergic asthma. J Clin Investig 2003; 112:566-574
65. Hollingsworth JW, Theriot BS, Li Z, et al. Both hematopoietic-Derived and non-hematopoietic-Derived b-Arrestin-2 regulates murine allergic airway disease. Am J Respir Cell Mol Biol 2010; 43:269-275
66. Shenoy SK, Lefkowitz RJ. b-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 2011; 32:521-533
67. Houslay MD. Arrestin times for developing antipsychotics and beta-blockers. Sci Signal 2009; 2:1-5
68. Jin SL, Goya S, Nakae S, et al. Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010; 126:1252-1259
69. Nguyen LP, Lin R, Parra S, et al. Beta2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A 2009; 106:2435-2440
70. Thanawala VJ, Forkuo GS, Al-Sawalha N, et al. b2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model. Am J Respir Cell Mol Biol 2013; 48:220-229
71. Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of beta-Adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A 2004; 101:4948-4953
72. Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38:256-262
73. Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the betablocker, nadolol, in mild asthma: An open-label pilot study. Pulm Pharmacol Ther 2008; 21:134-141
74. Hanania NA, Mannava B, Franklin AE, et al. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J 2010; 36: 963-965
75. Short PM, Williamson PA, Anderson WJ, et al. Randomized placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. Am J Respir Crit Care Med 2013; 187:1308-1314
76. Tashkin DP, Celli BR, Senn S, et al. A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2007; 359:1543-1554
77. Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: TheGLOW2 study. Eur Respir J 2012; 40:1106-1114
78. Beier J, Kirsten A-M, MrÛ z R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-To-severe chronic obstructive pulmonary disease: Results from a 6-week, randomized, controlled phase IIIb study. COPD 2013; 10:511-522
79. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-Acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013; 185:393-399
80. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of oncedaily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107:1538-1546
81. Sykes DA, Dowling MR, Leighton-Davies J, et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012; 343:520-528
82. Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of longacting muscarinic antagonists: Comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009; 330:660-668
83. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009; 331:740-751
84. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): A novel, long-Acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 2013; 345:260-270
85. Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367:1198-1207
86. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363:1715-1726
87. Casarosa P, Kiechle T, Sieger P, et al. The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics. J Pharmacol Exp Ther 2009; 333:201-209
88. Bateman ED, Rennard S, Barnes PJ, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009; 22:533-542
89. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: A randomised, double-blind comparison. Thorax 2012; 67:781-788
90. Compton C, McBryan D, Bucchioni E, et al. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2013; 26:562-573
91. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1:199-209
92. Wielders PLML, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: A trial with GSK961081. Eur Respir J 2013; 42:972-981